Long Term Efficacy of Faricimab Using a Treat and Extend Regimen for Type 3 Macular Neovascularization

Clinical trial NCT07187804 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07187804
Sponsor: Kim's Eye Hospital
Status: NOT_YET_RECRUITING
Phase: Phase 4
Study type: INTERVENTIONAL

Age-related Macular Degeneration (ARMD)Choroidal Neovascularization Anti-vascular Endothelial Growth Factor

Start date: 2025-09-23
Primary completion: 2028-09-22
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.